Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel in moderate to severe active SLE
NCT05765006Phase 1Recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmacabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoints: Dose Limiting Toxicity Rate at 3 months and Recommended Phase 2 Dose at 3 months. Started Feb 2023; status: recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05765006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765006.